FDA Report on Postmarketing Requirements for Drug and Biologics Firms

Summary

The FDA is required to annually report on the status of postmarketing studies and clinical trials for approved drug and biologics products under the 1997 Modernization Act, as the agency tracks the studies and trials agreed upon by applicants or required by the FDA.